You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Orexin receptor antagonists as therapeutic agents for insomnia
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2013
|
| DOI | 10.3389/fphar.2013.00163 |
| Pubmed ID | |
| Authors |
Ana C. Equihua, Alberto K. De La Herrán-Arita, Rene Drucker-Colin |
| Abstract |
Insomnia is a common clinical condition characterized by difficulty initiating or maintaining sleep, or non-restorative sleep with impairment of daytime functioning. Currently, treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) and pharmacological therapy. Among pharmacological interventions, the most evidence exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although concerns persist regarding their safety and their limited efficacy. The use of these hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) neuropeptides have been shown to regulate transitions between wakefulness and sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the development of a new class of pharmacological agents that antagonize the physiological effects of orexin. The development of these agents may lead to novel therapies for insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed arousal, and motor balance difficulties). However, antagonizing a system that regulates the sleep-wake cycle may create an entirely different side effect profile. In this review, we discuss the role of orexin and its receptors on the sleep-wake cycle and that of orexin antagonists in the treatment of insomnia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| France | 1 | <1% |
| Unknown | 111 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 16% |
| Student > Bachelor | 16 | 14% |
| Student > Ph. D. Student | 11 | 10% |
| Student > Master | 11 | 10% |
| Student > Doctoral Student | 10 | 9% |
| Other | 19 | 17% |
| Unknown | 28 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 22% |
| Neuroscience | 15 | 13% |
| Agricultural and Biological Sciences | 13 | 12% |
| Psychology | 8 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 16 | 14% |
| Unknown | 32 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2022.
All research outputs
#4,741,668
of 23,341,064 outputs
Outputs from Frontiers in Pharmacology
#2,074
of 16,798 outputs
Outputs of similar age
#50,365
of 283,867 outputs
Outputs of similar age from Frontiers in Pharmacology
#27
of 167 outputs
Altmetric has tracked 23,341,064 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,798 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,867 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 167 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.